Constance Benson
Expertise in
1
conditions

Dr. Constance Benson

Infectious Disease
UC San Diego
200 W Arbor Dr, 
San Diego, CA 
43 Years of Experience
Expertise in
1
conditions
UC San Diego
200 W Arbor Dr, 
San Diego, CA 

Overview

Constance Benson is an Infectious Disease provider in San Diego, California. Dr. Benson has been practicing medicine for over 43 years is highly rated in 1 condition, according to our data. Her top areas of expertise are HIV/AIDS, Toxocariasis, COVID-19, and Severe Acute Respiratory Syndrome (SARS).

Her clinical research consists of co-authoring 113 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Infectious Disease

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UC San Diego
200 W Arbor Dr, San Diego, CA 92103
Other Locations
UCSD Research Pharmacy
220 Dickinson St Ste A, San Diego, CA 92103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Digital Health Feedback System (DHFS) for Anti-Retroviral Therapy Medication Adherence and Transitions of Care Support During Hospital Admissions for Persons Living With HIV
Digital Health Feedback System (DHFS) for Anti-Retroviral Therapy Medication Adherence and Transitions of Care Support During Hospital Admissions for Persons Living With HIV
Enrollment Status: Completed
Publish Date: December 16, 2024
Intervention Type: Device
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
A Prospective Single Arm Open Label Intervention Study Using the DHFS With HIV Infected Participants Initiating or Continuing HIV Treatment
A Prospective Single Arm Open Label Intervention Study Using the DHFS With HIV Infected Participants Initiating or Continuing HIV Treatment
Enrollment Status: Unknown
Publish Date: December 23, 2022
Intervention Type: Device
Study Phase: Phase 4
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Enrollment Status: Completed
Publish Date: October 14, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

113 Total Publications

Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
Journal: The Journal of infectious diseases
Published: November 20, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Edward Cachay
Infectious Disease
Expertise in
9
conditions
Dr. Edward Cachay
Infectious Disease

UC San Diego

200 W Arbor Dr, 
San Diego, CA 
 (0.1 miles away)
619-543-3995
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Cachay is an Infectious Disease provider in San Diego, California. Dr. Cachay is highly rated in 9 conditions, according to our data. His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Myelitis.

Expertise in
4
conditions
Dr. Adriana Tremoulet
Infectious Disease
Expertise in
4
conditions
Dr. Adriana Tremoulet
Infectious Disease

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (3.2 miles away)
858-966-7785
Languages Spoken:
English
See accepted insurances

Adriana Tremoulet is an Infectious Disease provider in San Diego, California. Dr. Tremoulet is highly rated in 4 conditions, according to our data. Her top areas of expertise are Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Pediatric Myocarditis, and Severe Acute Respiratory Syndrome (SARS).

Expertise in
7
conditions
Dr. George Sakoulas
Infectious Disease
Expertise in
7
conditions
Dr. George Sakoulas
Infectious Disease

Sharp Rees-Stealy Medical Group-Genesee

2020 Genesee Ave, 
San Diego, CA 
 (2.6 miles away)
858-499-2600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

George Sakoulas is an Infectious Disease provider in San Diego, California. Dr. Sakoulas is highly rated in 7 conditions, according to our data. His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Endocarditis, and Osteomyelitis.

Frequently Asked Questions about Dr. Constance Benson

How do I make an appointment with Dr. Constance Benson?

You can book an appointment with Dr. Constance Benson by calling their office at 619-543-3995. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Constance Benson a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Constance Benson is classified as an Advanced expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Constance Benson specialize in?

While Dr. Constance Benson is a Infectious Disease, they have specific expertise in HIV/AIDS, Toxocariasis, and COVID-19. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Constance Benson participate in research or clinical trials?

Yes. Dr. Constance Benson has published 113 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Constance Benson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Constance Benson accept my insurance?

Dr. Constance Benson accepts most major insurance plans, including Humana. We recommend calling the office directly at 619-543-3995 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Benson's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile